SCHEMBL30925566

SCHEMBL30925566

Cc1cccnc1S(=O)(=O)Nc1c(N2CCOCC2)ccc2cccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 3/20 0.52
▸ SLC40A1 Q9NP59 8/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ NCOA1 Q15788 1/20 0.41
▸ SCN5A Q14524 1/20 0.41
▸ CNR1 P21554 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MDM4 O15151 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214257 1.00 SCN9A (0.52) SCN9ASLC40A1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL30925406 0.81 SLC40A1 (0.48) SCN9ASLC40A1L3MBTL1MEN1KMT2A
SCHEMBL27214253 0.81 SLC40A1 (0.48) SCN9ASLC40A1L3MBTL1MEN1KMT2A
SCHEMBL30925412 0.76 SLC40A1 (0.68) SLC40A1MEN1KMT2ATDP1ALDH1A1
SCHEMBL27214195 0.75 SLC40A1 (0.47) SLC40A1L3MBTL1MEN1KMT2ATDP1
SCHEMBL30925573 0.75 SLC40A1 (0.47) SLC40A1L3MBTL1MEN1KMT2ATDP1
SCHEMBL30925398 0.74 SLC40A1 (0.51) SLC40A1MEN1KMT2ATDP1ALDH1A1
SCHEMBL30925456 0.74 SLC40A1 (0.72) SLC40A1SMN1; SMN2KDM4EHPGDMEN1
SCHEMBL27214322 0.74 SLC40A1 (0.72) SLC40A1SMN1; SMN2KDM4EHPGDMEN1
SCHEMBL30925535 0.71 SLC40A1 (0.73) SLC40A1MEN1KMT2ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SCN9A 432/4885SLC40A1 3357/4885L3MBTL1 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback